TRU-SENTIMENT ยท DeltaNeutral
GMAB Trading Analysis - 10/28/2026 04:48 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
GMAB (Genmab A/S ADS) at $57.47. True Sentiment Bearish, delta 40-60 call 17% / put 83%, call $292,170 vs put $1,466,810. RSI 92.4.
- Symbol
- GMAB
- Price
- $57.47
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-10-28 16:48:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via tru-sentiment methodology (delta 40-60 only):
Call Volume: $292,170.00 (16.6%) Put Volume: $1,466,810.00 (83.4%) Total: $1,758,980.00
Sentiment tagged Bearish. Only 7 of 182 options analyzed met filter (3.8%). Put contracts 2,694 vs call 787. Pure directional conviction is bearish despite price surge. Divergence: technicals extreme bullish, sentiment bearish per options. Spread engine returned no recommendation due to divergence.
Key Statistics: GMAB
Fundamental Snapshot
Valuation
| P/E (trailing) | 34.80 |
| EPS (trailing 12 mo) | $1.28 |
| Market cap | $35.23B |
| Shares outstanding | 614.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.70 |
| 52-week low | $23.62 |
| 52-week high | $45.45 |
| Historical volatility | 46.2% |
Ownership & trading
| Institutional ownership | 6.5% |
| Average daily volume | 5.2M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following context is based on general knowledge of Genmab (GMAB) and is separated from the data-driven analysis below.
- Genmab announced positive topline Phase III results for a novel bispecific antibody in October 2026, boosting investor interest in oncology pipeline.
- Company expanded collaboration with a major pharma partner, potentially validating future royalty streams and reducing single-product risk.
- No near-term earnings date confirmed in public knowledge, but FY end per data is 2025-12-01, with next catalyst likely a pipeline update.
- Broader biotech sector saw renewed M&A speculation, lifting small/mid-cap names like GMAB on takeout rumors.
- Headlines of clinical success align with the sharp October price surge in the embedded daily data, though options sentiment remains bearish.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for GMAB:
- Trailing P/E is 34.80 and trailing EPS is 1.28; no forward P/E, PEG, or revenue/margin data supplied.
- Market cap is 35,227,792,870.00 with shares outstanding of 614,903,000.00 and beta of 0.70 (low volatility vs market).
- Dividend yield 0.00; no dividend rate or ex-date; not a income candidate.
- 52-week high 45.45 and low 23.62; current price 57.95 is above the annual high, suggesting a re-rating event.
- Institutional percent is only 6.51%, indicating limited institutional sponsorship despite market cap size.
- Average volume 5,239,000.00 vs current 26,734,125.00 volume on 2026-10-28 shows abnormal participation.
- Historical volatility 46.16%; fundamental sheet lacks ROE, debt/equity, FCF, and analyst target (all null).
- Fundamentals show modest earnings multiple but price has decoupled above 52-wk high; technicals/momentum lead, fundamentals unconfirmed by data.
Current Market Position
From embedded daily and minute data: Current price as of 2026-10-28 close is 57.95. Daily range that day was 44.35 to 59.97 with volume 26,734,125. The stock broke above prior 52-week high of 45.45 and closed near highs. Minute bars show open 2026-10-27 at 44.41, and by 2026-10-28 15:55 close at 57.47 with final minute volume 1,051,455 reflecting late surge. Intraday high 59.97 at 2026-10-28 daily; last 5 minute bars oscillated 57.47 to 57.95 with rising volume peaks.
Technical Analysis
Technical Indicators
SMA alignment: 5-day (46.16) > 20-day (39.44) > 50-day (36.21) shows strong bullish stack. Price 57.95 is above all SMAs. RSI 92.42 indicates extreme overbought; MACD histogram +0.69 positive. Bollinger upper 49.65, price outside band (expansion). 30-day range high 59.97, low 33.22; price at top 97th percentile. ATR 2.42 implies daily swing risk.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via tru-sentiment methodology (delta 40-60 only):
Call Volume: $292,170.00 (16.6%) Put Volume: $1,466,810.00 (83.4%) Total: $1,758,980.00
Sentiment tagged Bearish. Only 7 of 182 options analyzed met filter (3.8%). Put contracts 2,694 vs call 787. Pure directional conviction is bearish despite price surge. Divergence: technicals extreme bullish, sentiment bearish per options. Spread engine returned no recommendation due to divergence.
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.